Podcasts about biotech

Our CIO and Chief U.S. Equity Strategist Mike Wilson explains why market leadership is rotating beyond semiconductors and where investors may find opportunities despite near-term volatility.Read more insights from Morgan Stanley.----- Transcript ----- Welcome to Thoughts on the Market. I'm Mike Wilson, Morgan Stanley's CIO and Chief U.S. Equity Strategist. Today on the podcast, I will explain why the recent volatility in markets makes sense. It's Wednesday, July 22nd at 2 p.m. in New York. So, let's get after it. The broadening trade is back and it's gaining steam. We established this thesis last week. Importantly, there's a key reason this broadening trade is likely to continue. One of the more crowded areas of the market—semiconductors—has lost its momentum. As I've also noted before, this is not a call that the AI cycle is over. However, stocks do trade on the rate of change in growth, and expectations often reach a place where they can no longer surprise on the upside. Earnings revisions tend to get too stretched, and capital starts looking for the next place where fundamentals are improving but positioning is still light. This is no different than what happened to other leadership groups earlier this year in areas like precious metals and energy stocks. Remember, I first made the call for market broadening in our November outlook. My view is that the economy had moved into a new expansion after the rolling recession ended in April 2025. Markets were starting to catch on before the Iran conflict interrupted that trend. Investors piled back into the AI trade—especially semis—as oil prices jumped and Fed expectations shifted more hawkish. Back in June, I noted that those earnings revisions were likely nearing their peak. Hyperscale stocks starting to lag was the first indication. Since semis ultimately depend on hyperscaler spending, that divergence usually doesn't last. It doesn't mean the buildout is ending. However, the spenders may be moving from blind enthusiasm to a more disciplined phase as a means of addressing the market's concerns about falling cash flows. We've seen this pattern before. Since ChatGPT launched, this ebbing and flowing between the hyperscaler and semiconductor stocks has happened three times. This is the fourth such adjustment, during which the hyperscaler stocks are likely to outperform the semis. Since a few weeks back, hyperscalers have outperformed semiconductors by almost 30 percent. Another consequence is that the major averages may trade lower in the near term. When a crowded, large-cap leadership group is unwinding, the index can look choppy even as the market underneath is improving. That's the key distinction. The index may struggle, but the broadening can still work. Over the next month, don't be surprised if the S&P 500 trades as low as 7000 before it makes a move to 8000 by year-end. Use this weakness to add to equity positions. I continue to like Consumer Discretionary Goods, Transports, and Biotech. Discretionary Goods remains one of the cleaner expressions of the broadening thesis. Wallet share is shifting from services back toward goods, goods pricing is improving, and earnings revisions are strengthening. Transports continue to show improving revisions as volumes stabilize and pricing gets better. Biotech is one of the more attractive lower-rate beneficiaries, especially if policy expectations are too hawkish, as I think they are. On that last point, the Fed backdrop matters. The June FOMC meeting told us forward guidance is going to be limited, and the inflation path is going to drive policy. The softer-than-expected inflation data last week should allow the Fed to stay on hold rather than hiking. It may take the bond market a few more data points to fully re-price this view. Bottom line, the broadening is in gear, but it may not feel comfortable because it's happening while the crowded momentum trade unwinds, a process that is likely unfinished. That's usually how rotations in market leadership work. Like spring, it's often: in like a lion and out like a lamb. Thanks for tuning in. I hope you found it informative and useful. Let us know what you think by leaving us a review. And if you find Thoughts on the Market worthwhile, tell a friend or colleague to try it out!

Vasanta Pundarika built her career inside healthcare investment banking before launching Lotuspring, an advisory firm focused on women's health and behavioral health. She spent nearly 20 years advising healthcare systems, treatment providers, and growth stage companies on mergers, financing, and operational strategy while watching the industry repeatedly misunderstand the people it claimed to serve.The conversation starts unexpectedly with anthropology, bread, and language. Vasanta explains how she spent years changing the pronunciation of her own name to make other people comfortable before eventually reclaiming it. That thread opens into a much larger discussion about adaptation, identity, and what institutions quietly train people to tolerate.From there, the discussion moves into behavioral health, women delaying care, and the invisible labor that healthcare business models routinely ignore. During COVID, Vasanta noticed men's behavioral health units refilled faster than women's units. The reason had nothing to do with demand. Women were still home managing caregiving responsibilities, children, aging parents, and households while their own mental health collapsed in the background.The episode examines what happens when healthcare companies become “snazzy big brands” before building real clinical substance underneath. Vasanta describes the tension between mission and margin inside healthcare startups, private equity backed care models, and behavioral health expansion. The conversation pushes on who benefits when healthcare scales aggressively, who absorbs the operational pressure, and how patient trust erodes long before executives notice it on a dashboard.They also discuss patient advocacy culture, anthropology as systems analysis, healthcare capitalism, prior authorization, investor language, and why some clinically excellent companies never survive long enough to scale.RELATED LINKSVasanta PundarikaLotuspringWomen's Health HorizonsSakhi for South Asian SurvivorsNACDPrinceton University Anthropology DepartmentFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're navigating through a myriad of transformative advancements reshaping the industry. From artificial intelligence-driven research breakthroughs to strategic acquisitions in emerging therapeutic areas, these developments are setting new benchmarks in drug discovery and patient care. **Strategic Acquisitions and Expansions:** Samsung Biologics' recent proposal to acquire Swiss CDMO Polypeptide for $1.8 billion marks a significant expansion into peptide production, underscoring the growing therapeutic importance of peptides. Their specificity and efficacy make them particularly appealing for metabolic disorders such as obesity. This acquisition reflects a strategic move to capture emerging market opportunities as demand for innovative metabolic treatments rises. Eli Lilly's bold $2.8 billion acquisition of Atai-Beckley highlights the pharmaceutical industry's shifting focus towards psychedelics. As mental health disorders like depression and PTSD become more prominent, psychedelics hold great promise for new therapeutic approaches. This acquisition may pave the way for further research and acceptance of psychedelics within mainstream medicine, offering new hope for patients. Another notable development is Tempus' acquisition of Personalisis for $1.5 billion. This move strengthens Tempus' cancer treatment portfolio by leveraging genomics-driven insights, emphasizing precision medicine's critical role in oncology. **AI Integration and Technological Innovation:** Bristol Myers Squibb is doubling down on AI integration by expanding its collaboration with Nvidia to build what promises to be the most powerful AI supercomputer dedicated to life sciences. This development is pivotal as it signifies a deeper commitment to harnessing computational power in R&D. By accelerating drug discovery and optimizing clinical trial processes, AI stands to revolutionize how treatments are developed and tailored to individual patients. Overall, these developments indicate a dynamic phase characterized by technological innovation and strategic collaborations. The integration of AI into drug development processes stands out as a transformative force, promising enhanced efficiency and efficacy in bringing new treatments to market. **Regulatory Milestones and Clinical Trials:** In regulatory news, Takeda's Qdenga has achieved a milestone by becoming India's first approved dengue vaccine. This approval is crucial in addressing neglected tropical diseases, with significant implications for public health in regions where dengue is prevalent. By reducing dengue fever incidence, this vaccine could play a vital role in improving health outcomes in many tropical countries. Promising results have emerged from clinical trials across various therapeutic areas. 4D Molecular Therapeutics reported an 87% reduction in treatment burden for wet AMD using their gene therapy candidate 4D-150 in Phase 2b trials—demonstrating potential as a transformative approach with reduced intervention frequency. Latigo Biotherapeutics' Nav1.8 inhibitor LTG-001 outperformed Vicodin in Phase 2 trials for acute pain, offering a non-opioid alternative amidst the opioid crisis. Meanwhile, Regenxbio's five-year data on surabgene lomparvovec shows sustained efficacy in wet AMD and diabetic retinopathy—underscoring its potential as a long-term treatment option. **Financial Performance and IPO Activity:** Financially, Abbott exceeded expectations with strong sales from their device and diagnostic divisions, prompting an upward revision of their full-year profit forecast. This reflects sustained demand for innovative diagnostic solutions and medical devices—highlighting Abbott's strategic market positioning. The IPO landscape remains active with companies like Nuvox Therapeutics seeking to raise funds for advancing oxygen therapeutics targeting hypoxia-related diseases—showcasing renewed investor interest and confidence within biotech innovation. Latigo Biotherapeutics is preparing for an IPO to advance its pipeline, demonstrating a strategic response to the opioid crisis. By developing alternatives that minimize addiction risks while providing effective relief, Latigo underscores the industry's commitment to safer pain management solutions. Turning to clinical trials, Scribe Therapeutics plans a $96 million IPO to advance its CRISPR-based lipid-lowering therapies, marking significant interest in genetic solutions for cardiovascular diseases like hyperlipidemia. The precision offered by CRISPR technology could revolutionize treatment options for conditions contributing significantly to cardiovascular health burdens. **Geopolitical Influences:** Geopolitical factors are also influencing market dynamics, particularly in the UK biotech sector where IPO plans are being shaped by global uncertainties despite robust venture capital backing. This situation underscores the complex interplay between regional economic conditions and global investment trends in biotech innovation. As these trends continue unfolding across the industry landscape—from AI-driven research advancements to strategic acquisitions—the potential impact on patient care paradigms remains profound. These developments not only promise new possibilities within drug development but also influence broader healthcare delivery models aimed at improving patient outcomes globally.Support the show

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Matt Winton, Ph.D., Chief Commercial and Business Officer at CervoMed, talks about preparing for the late-stage development of neflamapimod in dementia with Lewy bodies (DLB) and commercial planning for an anticipated launch. Winton talks about CMC and manufacturing scale-up, partnership, communicating with regulators and the benefits of global regulatory alignment on protocols for the Phase 3 trial. He also talks about building value through HEOR and payer engagement in parallel with clinical development, and pricing in the context of policy changes and shifting global launch dynamics.           Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of industry-shaping events, reflecting the ever-evolving landscape of drug development, regulatory challenges, and strategic maneuvers. In a significant move within the sector, Jasper Therapeutics has merged with Kira Pharmaceuticals, a strategic decision aimed at expanding its footprint in autoimmune therapeutics. This merger brings to Jasper a valuable asset in KP-104, a dual-inhibitor with the potential to address rare diseases—an area of considerable unmet need. Such consolidations highlight an industry trend where companies seek to bolster their portfolios with promising candidates that can tackle complex medical conditions. The merger exemplifies how strategic expansions are becoming increasingly integral to maintaining competitive edges in the biotech arena. Turning to clinical trials, Takeda's Zasocitinib has demonstrated promising results for patients suffering from moderate-to-severe plaque psoriasis. In Phase 3 trials, a significant 75% of patients achieved clearance of scalp psoriasis. Zasocitinib operates as a TYK2 inhibitor, targeting the IL-23 pathway—a crucial mechanism in autoimmune diseases like psoriasis. This breakthrough promises to enhance patient care by providing a more effective treatment option for those struggling with difficult-to-treat psoriasis. On the regulatory front, Novartis' Fabhalta (Iptacopan) has gained FDA approval for its role in slowing kidney function decline in patients with primary immunoglobulin A nephropathy. As a small molecule complement inhibitor, Iptacopan introduces a novel treatment class for this autoimmune kidney disorder. This approval underscores ongoing innovation within nephrology and offers renewed hope for improved patient outcomes. Recent regulatory updates also saw Novartis securing full FDA approval for Fabhalta—an affirmation of progress in addressing immunoglobulin A nephropathy through innovative therapeutic options. Business development remains a driving force in shaping industry landscapes. The acquisition of Mission Therapeutics' AKI candidate MTX652 by Dimerix is a prime example. This $5 million deal, with potential milestones up to $292 million, reflects high stakes and ambitions to advance treatments for acute kidney injuries—a field with significant unmet medical needs. The integration of artificial intelligence continues to revolutionize drug discovery processes. Aqemia's collaboration with Sanofi highlights this trend, showcasing AI's crucial role in expediting drug development and uncovering novel therapeutic targets. Their partnership potentially worth $140 million underscores AI's transformative potential within pharmaceutical research. Notably, Nobel laureate Jennifer Doudna's foray into AI-powered protein design signifies an exciting intersection between gene-editing technology and artificial intelligence. Her involvement signals potential revolutions in drug discovery through enhanced precision in protein engineering. However, regulatory challenges persistently loom over the industry. Novo Nordisk and Alvotech have faced FDA scrutiny concerning manufacturing deficiencies—an issue that accentuates the importance of stringent quality control and operational excellence in biologics manufacturing. The American Society of Health-System Pharmacists (ASHP) report on U.S. drug shortages during Q2 2026 reveals vulnerabilities within supply chains, notably impacting oncology drugs. These shortages emphasize the critical need for robust strategies to ensure consistent drug availability for essential therapies. Furthermore, geopolitical dynamics are influencing pharmaceutical supply chains. A U.S. Senate bill aimed at increasing transparency highlights concerns over China's dominance in drug ingredient supplies—an issue necessitating strategic adjustments by globally operating companies. Elsewhere within the sector, GSK made headlines by discontinuing the development of its chronic cough treatment camlipixant following mixed Phase 3 trial results—a setback illustrating the critical nature of trial outcomes in determining drug viability and market potential. In market trends, biotech IPOs have surged during the first half of 2026—a sign of robust investor interest fueled by innovations and favorable funding environments despite associated market volatility risks. Strategic adjustments continue across companies with mergers and acquisitions leading to workforce reductions—projected layoffs exceeding 14,000 within biopharma during H1 2026—as organizations streamline operations or pivot towards more promising research domains. Lastly, Merck's FDA approval for an oral PCSK9 inhibitor marks a significant achievement in cardiovascular care—representing another stride forward in therapeutic innovation. In summary, these developments encapsulate a landscape defined by scientific pursuits yielding mixed results amidst evolving regulatory interactions and strategic realignments—all contributing towards innovative healthcare solutions while navigating complex industry dynamics.Support the show

Lexikon zur Folge: oaws.de/bbbiotech. BB Biotech (WKN: A0NFN3) ist kein Biotech-Unternehmen. Auch kein Biotech-Fonds. Sondern eine Firma, die ihr komplettes Kapital in Biotech-Aktien investiert. Wie machen sie das? Was muss man bei Biotech-Investments beachten? Kann man in dem Markt überhaupt noch Geld verdienen oder hat man keine Chance gegen Hedgefonds? Das alles haben wir mit dem Chef von BB Biotech, Dr. Christian Koch, besprochen. Außerdem geht's um die Rolle von Europa in der globalen Biotech-Industrie, wie KI den Investmentprozess verändert und und und. Hier geht's zum DJE Fonds Multi Asset & Trends: https://www.dje.de/de/investmentfonds/productdetail/LU0159549145/#fondsuebersicht Aktien hören ist gut. Aktien kaufen ist besser. Bei unserem Partner Scalable Capital geht's unbegrenzt per Trading-Flatrate und auf der hauseigenen European Investor Exchange, die genau auf Privatanleger zugeschnitten ist. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Diesen Podcast vom 18.07.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Boston. San Francisco. Beijing? The global biotech industry has long been concentrated in a handful of cities. But which emerging hubs could become dominant forces in biotech in the decades ahead? In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia and Will Maddox discuss a new Fierce special report identifying five cities with the potential to become major forces in the global biotech industry. Did your favorite city make the cut? Listen to find out. To learn more about the topics in this episode: Top emerging biotech hubs in 2026 As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’ British biotech VC funding shows ‘signs of recovery,’ but IPO rebound yet to materialize Could Basel be the next Boston? How the Swiss biotech hub is quietly raising its game This week's episode is sponsored by IQVIA Biotech. Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.comSee omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to forge ahead, making significant strides in scientific advancements, regulatory approvals, and strategic business developments. These moves are reshaping the landscape of drug development and patient care. Starting with Merck & Co.'s recent FDA approval for Lipfendra, the world's first oral PCSK9 inhibitor, this marks a pivotal shift in managing hypercholesterolemia. Traditionally, PCSK9 inhibitors have been administered via injection, but Lipfendra offers a more convenient oral alternative. This could significantly improve patient adherence and outcomes by easing the administration process for those managing cholesterol levels. The drug's approval highlights a crucial advancement in cardiovascular treatment, with expectations of reaching peak annual sales of $5 billion, underscoring its market potential. In another significant development, Eli Lilly has entered the burgeoning field of psychedelic therapeutics with its acquisition of Ataibeckley for up to $3.8 billion. This move reflects a growing trend toward exploring novel therapeutic avenues for psychiatric disorders. Psychedelic compounds promise new hope for patients with depression and other mental health conditions where conventional therapies have shown limited efficacy. Eli Lilly's investment signals confidence in the transformative potential of psychedelics, which could revolutionize treatment paradigms for conditions like depression and PTSD. Turning to obesity treatment, Novo Nordisk's Wegovy pill has received European Commission approval for obesity and overweight adults. As a small molecule GLP-1 receptor agonist, semaglutide enhances satiety and reduces caloric intake. This development underscores the increasing focus on metabolic disorders and highlights the competitive landscape as companies race to dominate the weight management sector with innovative oral formulations. In oncology news, Merck & Co.'s Keytruda has achieved a milestone in becoming the first PD-1 inhibitor to demonstrate phase 3 benefits as a single agent in frontline mismatch repair-deficient endometrial cancer. This success not only reinforces Keytruda's role in oncology but also emphasizes the importance of precision medicine approaches targeting specific genetic mutations in cancer therapy. The industry is also seeing substantial financial maneuvers aimed at bolstering research capabilities and market reach. Johnson & Johnson has raised its 2026 financial guidance following Tremfya's impressive $2 billion revenue milestone with its IL-23 inhibitor for autoimmune diseases. Additionally, their strategic supply chain restructuring reflects efforts to enhance operational efficiency amid a broader U.S. manufacturing push. On the regulatory front, Johnson & Johnson received UK MHRA approval for Akeega in BRCA1/2-mutated metastatic prostate cancer, highlighting ongoing focus on precision medicine and targeted therapies in oncology. Meanwhile, Medtronic's recall of Harmony Catheter Delivery Systems due to safety concerns serves as a reminder of ongoing vigilance in medical device safety regulations. In clinical trial advancements, InnoCare Pharma's TYK2 inhibitor demonstrated efficacy in a Phase 2 trial for nonsegmental vitiligo, achieving its primary endpoint and paving the way for Phase 3 studies. This highlights TYK2 inhibition as a promising strategy for autoimmune diseases like vitiligo. Moreover, we witness movements towards public offerings with companies like Vogenx and Braveheart Bio aiming for IPOs to fund their respective drug development projects. These efforts underscore the continuous drive for capital to propel innovative therapies through clinical trials and towards commercialization. Finally, turning to regulatory updates, Sanofi has entered new chapters in mRNA patent litigation against Pfizer and Moderna, reflecting ongoing tensions over intellectual property rights within the high-stakes realm of COVID-19 vaccines and mRNA technology. The outcomes here could have far-reaching implications for mRNA-based therapeutics and vaccine development. As we look at these developments collectively, they illustrate a vibrant period for pharmaceutical and biotech companies innovating new treatments while navigating complex regulatory terrains. The implications for patient care are profound, with potential improvements in therapeutic options driven by new scientific breakthroughs and strategic industry shifts. These dynamics promise to reshape the future landscape of global healthcare delivery and pharmaceutical innovation as these trends continue to unfold.Support the show

How to Launch a Biotech Startup in 2025 | Real Talk with Richard Bendis #richardbendis #healthtech #entrepreneurshipWhat does it really take to build a successful biotech startup in today's tough investment climate? Please visit our website to get more information: https://swangroup.net/ In this episode, I sit down with Richard Bendis, the powerhouse behind BioHealth Innovation, to unpack the raw reality of starting a life sciences company in 2025. From navigating non-dilutive funding and government partnerships to leveraging EIR programs and tech transfer strategies, we dive into the entrepreneurial ecosystem that's shaping the future of biotech. Richard's insights span decades of innovation policy, investment, and commercialization strategy - exactly what founders and future founders need right now. If you're looking to launch a biotech company or you're struggling with funding, this conversation is packed with practical knowledge.Links from this episode:✅ Get to know more about Richard Bendis:  https://www.linkedin.com/in/richbendis  ✅ Learn more about BioHealth Innovation: https://www.biohealthinnovation.org

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the latest advancements shaping the future of drug discovery and patient care. Veradermics is making significant strides with its oral minoxidil formulation aimed at addressing female pattern hair loss. The mid-stage clinical trial results have analysts optimistic about Veradermics' potential to capture a significant portion of this underserved market. The oral form of minoxidil, traditionally used in topical Rogaine products, offers a novel delivery method that could enhance patient adherence and improve outcomes, marking an innovative leap in dermatological treatments. Johnson & Johnson is navigating the expiration of Stelara's patent protection with resilience, as Tremfya steps up to fill the revenue gap. With quarterly sales exceeding $2 billion, Tremfya underscores the critical role of strategic lifecycle management and robust product pipelines in weathering patent cliffs. This success highlights the necessity for pharmaceutical companies to sustain growth through a well-rounded portfolio that can absorb such impacts. In oncology, Celcuity has achieved a pivotal milestone with FDA approval for its small molecule inhibitor targeting breast cancer. This therapy promises blockbuster potential and could become a new standard-of-care, expanding treatment options for patients. The approval reflects ongoing innovation in oncology, where small molecules continue to play an essential role alongside biologics in advancing cancer therapies. AI-driven drug discovery is gaining traction as Insilico Medicine partners with CDMO Bora in a potentially $2.5 billion deal. This collaboration underscores AI's transformative potential in accelerating drug discovery and development processes. By leveraging artificial intelligence, Insilico aims to identify new drug candidates more efficiently, expediting their journey from bench to bedside. Kelun-Biotech is marking significant progress with its SAC-TMT program targeting non-small cell lung cancer (NSCLC), filling gaps left by Merck's phase 3 efforts. This development is crucial for providing more tailored therapeutic options in oncology, illustrating how advancements in drug development are driving forward personalized medicine. Roche continues its exploration of Alzheimer's disease treatments with a multifaceted approach that includes both amyloid and tau proteins as targets. While its phase 3 amyloid program is prominent, Roche's interest in tau protein highlights the complexity of tackling neurological disorders and the need for diverse therapeutic strategies. Meanwhile, Biogen remains steadfast in defending its anti-tau Alzheimer's candidate following mixed phase 2 results that showed slowed cognitive decline. Despite stock volatility, this endeavor illustrates the high-stakes nature of Alzheimer's research as companies pursue novel approaches to this challenging disease. Regulatory landscapes are also shifting as Johnson & Johnson halts development of an eye disease gene therapy after disappointing phase 2b results. This move reflects the inherent risks involved in gene therapy and underscores the necessity for thorough evaluation at each clinical stage. Medtronic's recall of its Harmony delivery catheter system due to potential detachment risks serves as a reminder of the paramount importance of safety and quality control in medical device manufacturing. Such recalls impact patient safety and emphasize regulatory vigilance over device reliability. In summary, these innovations demonstrate the dynamic nature of the pharma and biotech industries where cutting-edge science drives progress. Integrating AI into drug discovery, managing product lifecycles post-patent expiry, advancing personalized medicine, and maintaining regulatory diligence collectively shape a landscape focused on improving patient outcomes worldwide. Turning to recent scientific developments: Eli Lilly's presentation at AAIC 2026 on their anti-amyloid Alzheimer's drug Kisunla explores maintenance therapy possibilities once amyloid levels fall below a threshold. This potential shift could signify a paradigm change by extending therapeutic benefits and possibly improving long-term outcomes for patients with Alzheimer's. Biogen's advances with its anti-tau Alzheimer's therapy partnered with Ionis Pharmaceuticals further validate the tau hypothesis. The promising mid-stage data on their antisense drug Diranersen opens opportunities for other companies like Denali Therapeutics to explore similar avenues for treating neurodegenerative diseases. The industry is also witnessing a resurgence in biotech IPOs during 2026's first half, recovering from a sluggish 2025. This surge signals investor confidence in biotechnological innovation while providing capital for advancing research pipelines. Financial activities within the sector are robust as Attovia Therapeutics files for an IPO to fund its competitive pipeline against Sanofi's Dupixent. Meanwhile, Advancell's $315 million Series D funding supports advancing prostate cancer candidates into Phase 3 trials, backed by big pharma confidence in radiotherapy's potential. Lastly, regulatory transparency improves as the FDA resumes releasing drug rejection letters after a temporary pause—a move likely to influence future submissions significantly by offering clearer guidance on regulatory expectations. These developments collectively highlight how scientific innovation and strategic maneuvers transform pharmaceutical landscapes, promising profound impacts on patient care through advanced therapies and novel treatments worldwide. As these trends unfold, they reflect an industry increasingly reliant on technological integration and collaborations to drive future growth and innovation.Support the show

“I think this is an incredible time to be investing in biotech.” Dr. Simeon George, founder and CEO of SR One, joins Bloomberg Intelligence analyst Sam Fazeli to explain why biotech’s next cycle will be global, selective and unforgiving. George traces SR One’s evolution from one of pharma’s oldest corporate venture arms to an independent firm with more than $2 billion raised. The conversation explores why AI’s real test is cutting development time and attrition, not just discovering targets, while also laying out SR One’s view on oncology crowding, neuro’s blood-brain-barrier challenge, China’s accelerating role in drug innovation and the importance of building companies around medicines that can truly change standard of care.See omnystudio.com/listener for privacy information.

A bioinformática está transformando a medicina ao integrar biologia, ciência de dados e inteligência artificial para acelerar diagnósticos, desenvolver novos medicamentos e impulsionar a medicina de precisão.Neste episódio do podcast Biotech and Health, da MIT Technology Review Brasil, Carolina Abelin e Camila Pepe conversam com Helder Nakaya, pesquisador do Hospital Israelita Albert Einstein e professor da USP. O especialista explica como grandes volumes de dados biológicos podem ser utilizados para compreender doenças, prever respostas a tratamentos e apoiar o desenvolvimento de terapias cada vez mais personalizadas. 

Why can some people effortlessly build professional relationships through networking? The work starts long before they ever walk into the room.In this first installment of a three-part networking series, Elaine Hamm, PhD, is joined by special guest host James Zanewicz, JD, LLM, RTTP, to explore why preparation is the most overlooked part of successful networking. From researching attendees to refining your personal pitch, they share practical strategies that help professionals build authentic relationships with greater confidence and purpose. Whether you're attending a major biotech conference, investor meeting, or local networking event, the right preparation can make every conversation more meaningful.In this episode, you'll learn:How researching attendees and defining your networking goals can make every event more productive.Why a well-prepared story, elevator pitch, and leave-behind materials create stronger first impressions.Practical ways to use LinkedIn, AI tools, and thoughtful preparation to reduce anxiety and build genuine professional relationships.Join Elaine and James as they kick off this three-part series on networking by showing why the most successful conversations begin long before you ever step into the room.Links: Connect with James Zanewicz, JD, LLM, RTTP, and learn about Connect.Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine.Check out Elaine's book recommendations: The Fine Art of Small Talk, The Speed of Trust, How to Talk to Anyone, and The Vault Guide to Schmoozing.Learn more about The Alliance for Artificial Intelligence in Healthcare.Check out our previous episode on Networking for Introverts.Connect with Ian McLachlan, BIO from the BAYOU producer.Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into an array of groundbreaking advancements and strategic movements reshaping the landscape of healthcare and medicine. Recent strides in Alzheimer's research have highlighted Biogen's promising Phase 2 clinical trial results for diranersen, an antisense oligonucleotide targeting the tau protein. Unlike traditional amyloid-targeting therapies, this approach offers a novel mechanism that could diversify treatment options for Alzheimer's patients. By addressing tau pathology, a critical feature of Alzheimer's disease, Biogen's findings may influence research trajectories and potentially lead to improved patient outcomes. In tandem with this, Biogen and Eisai have received FDA approval for a subcutaneous formulation of Leqembi (lecanemab), targeting amyloid-beta plaques. This new delivery method is poised to enhance patient compliance and accessibility, marking significant progress in broadening Alzheimer's treatment modalities. In oncology, AstraZeneca has entered into a substantial $1.5 billion licensing agreement with Dizal Pharmaceutical for lung cancer therapies. This strategic partnership emphasizes the importance of collaborative efforts in advancing cancer treatment and highlights the role of targeted therapies in addressing unmet medical needs. Additionally, Merck KGaA's Erbitux has secured European Commission approval for first-line treatment of BRAF V600E-mutant metastatic colorectal cancer. By focusing on specific genetic mutations, this approval illustrates the shift towards precision medicine, where treatments are tailored based on individual genetic profiles. The industry is also embracing advanced technologies such as artificial intelligence (AI) to enhance drug discovery processes. Chai Discovery's partnership with Novartis exemplifies this trend, as they focus on AI-driven therapeutic antibody discovery. Meanwhile, Ardigen and Veraxa Biotech's collaboration in optimizing T-cell engager and ADC drug discovery demonstrates AI's growing role in reducing timeframes and costs associated with bringing new therapies to market. Regulatory updates from the FDA seek to streamline registration rules to alleviate manufacturing burdens for biopharma companies, reflecting ongoing efforts to improve operational efficiencies in drug production. Additionally, new guidance on psychedelics indicates a regulatory openness that could stimulate innovation within neurological therapeutics. In other news, HUYABIO's Phase 3 trial results have shown promise for advanced skin cancer patients through a combination therapy involving Bristol Myers Squibb's Opdivo. This success underscores the potential of combination therapies to enhance treatment efficacy. Meanwhile, cell therapy is experiencing a transformative shift with Cellares' advancements in automating manufacturing processes. These innovations promise broader access to life-saving cell therapies by accelerating production timelines and reducing costs. Turning to business developments, Spero Therapeutics' $1.1 billion deal with Innovent Biologics marks a strategic pivot towards immune modulation therapies, highlighting the growing interest in autoimmune diseases. Concurrently, Avere Therapeutics' public listing via a reverse merger with NextCure and acquisition of an IL-23 drug signifies ongoing consolidation within the sector. On the regulatory front, Beckman Coulter's expansion of its Alzheimer's diagnostic portfolio through a CE mark for its p-tau217 assay enhances diagnostic capabilities crucial for early detection and management amid an aging global population. As we look globally, cities like Basel and Beijing are emerging as biotech hubs, attracting top talent and investments while fostering innovation. Amid these shifts, industry professionals are encouraged to adapt to evolving technological landscapes, particularly with AI poised to enhance decision-making processes and streamline clinical workflows. These developments illustrate a dynamic phase for pharma and biotech sectors where scientific breakthroughs are closely intertwined with strategic business decisions and regulatory advancements. As we continue to navigate these changes, the potential for delivering more effective treatments across various therapeutic areas is immense. Stay tuned as we bring you more insights into how these innovations are shaping the future of healthcare globally. Thank you for joining us at Pharma Daily; until next time.Support the show

Our CIO and Chief U.S. Equity Strategist Mike Wilson discusses where investors may find opportunity beyond the AI sector and risks that could slow market gains.Read more insights from Morgan Stanley.----- Transcript -----Welcome to Thoughts on the Market. I'm Mike Wilson, Morgan Stanley's CIO and Chief U.S. Equity Strategist. Today on the podcast I'll be discussing our broadening thesis and the near-term risks to monitor. It's Tuesday, July 14th at 11:30 am in New York. So, let's get after it. The broadening trade is now playing out. It's showing up in stock prices, relative performance and earnings revisions. It's also making investors question the sustainability of the most crowded areas of the market, and consider other near-term risks. I first made the broadening call late last year based on my view that the economy had entered a new expansion after completing the rolling recession in April of 2025. In a new expansion, earnings growth tends to be much better than expected because revenue growth returns to companies that have already become more cost efficient. That's classic operating leverage. The market began to anticipate that dynamic late last year, but then the Iran conflict interrupted the move. Oil surged, rate-cut expectations disappeared, and investors crowded back into the most obvious AI capex beneficiaries led by semiconductors and memory, in particular. Since mid May, that interruption has faded with oil prices falling sharply and the broadening trade has begun to work again. Importantly, the market is not abandoning AI. It is simply rotating within AI and beyond AI. And that distinction matters. Semiconductors have had a historic run, supported by earnings revisions. But even great stories get exhausted in the short term. When earnings revisions breadth is pressing against historical highs and the trade becomes one of the most crowded areas of the market, the bar for upside gets very high. At that point, the issue is not whether the story is good. The issue is whether the rate of change can keep improving. That is a very different question. The underperformance of the hyperscalers was probably the first warning sign. Semis depend on hyperscaler capex. So when the spenders start lagging the beneficiaries, that divergence usually resolves one way or another. And now we're starting to see it. Meta's decision to sell excess capacity to outside customers may not mean the AI capex cycle is over. But it does tell you the market is beginning to ask harder questions about the path and pace of that spending. Credit spreads and stock prices of these hyperscalers provide the feedback loop to managements that maybe they should curtail the pace of spend. We've had multiple corrections inside this AI cycle already. This looks like another one – not the end of the cycle, but a reset. That reset is what gives the rest of the market room to work. Our preferred ways to express the broadening remain Consumer Discretionary Goods, Transports, and Biotech. These are not the areas investors have been excited about. In fact, positioning and sentiment remain subdued. But that's exactly why I like them. The risks to the story in the short term are two-fold. First, uncertainty about the full re-opening of the strait remains high, with pivots on both sides. This is keeping oil prices volatile in the short term even if the primary trend remains lower. Second, interest rate volatility is picking up again with the entire curve shifting higher in both nominal and real terms. If this doesn't stabilize, it will have a negative impact on stocks both at the index level and even for stocks that should benefit from our broadening call. With the inflation data coming in today softer than expected, this should reduce some of the recent upward pressure on rates. However, the new Fed Chair and board remain resolute to make sure inflation doesn't rear its head again. In the end, dealing with this risk up front is a good thing in my view even if it means uncertainty for markets. Bottom line, equity markets have been consolidating and correcting for the past several months. This is the result of the peak rate of change in earnings revisions and a reaction function shift at the Fed to focus more on the inflation mandate than growth. With the recent rollover in semiconductors, heavy supply of equity and credit issuance, and a transition of leadership at the Fed, expect more volatility and corrective activity in stocks before the next leg of the bull market resumes. Don't chase momentum. Instead, add to risk on down days to areas that will benefit from a broadening in the economy and earnings growth. Thanks for tuning in; I hope you found it informative and useful. Let us know what you think by leaving us a review. And if you find Thoughts on the Market worthwhile, tell a friend or colleague to try it out!

Brad Power spent years advising major corporations on systems design, process engineering, and decision making before lymphoma shoved him into the patient side of American healthcare. Instead of accepting the experience at face value, he started reverse engineering the machinery around cancer itself. Brad is the founder of Cancer Patient Lab and Open Cancer AI, two projects built around a blunt reality most patients discover too late: the healthcare system rewards people who know how to navigate it. Everyone else risks getting steamrolled by information asymmetry, insurance barriers, administrative friction, and institutional incentives designed around efficiency instead of human survival.The conversation starts with Harvard Business Review and Tumblr blogs before moving directly into the darker architecture underneath modern cancer care. Power explains how hospitals optimize for throughput, how insurance companies reward operational consistency over personalized medicine, and why many patients quietly end up needing a crash course in oncology, reimbursement policy, and behavioral psychology while fighting for their lives.The discussion digs into CAR-T therapy, functional testing, AI assisted decision support, and the growing collision between personalized medicine and standardized care pathways. Power argues that engaged patients often get better outcomes because they learn how to push for off guideline treatments, contest denials, and ask smarter questions. The counterpoint lands hard: patients should never have needed to become experts in the first place.The episode also explores the cultural consequences of AI entering cancer care. OpenAI advertising, data privacy, trust erosion, pharmaceutical influence, and “agentic AI” all collide inside a healthcare economy already drowning in distrust. Power sees artificial intelligence as a force multiplier for patient literacy and access. The larger system still decides who gets approved, who gets delayed, and who gets left behind.By the end, the conversation lands exactly where modern healthcare keeps forcing people to land: survival increasingly depends on learning how the machine works before the machine works on you.RELATED LINKSBrad PowerCancer Patient LabOpen Cancer AIHarvard Business ReviewResearch to the PeopleCAR T Cell TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest news and insights that are shaping the landscape of patient care and drug development. The U.S. FDA has expanded the label for Pfizer and Astellas' Padcev, in combination with Merck's Keytruda, to include all muscle-invasive bladder cancer patients. This significant regulatory update broadens access to a combination therapy that merges an antibody-drug conjugate with a PD-1 inhibitor, offering enhanced treatment options for patients unable to tolerate cisplatin, a common chemotherapy drug. The decision marks a pivotal step forward in providing more inclusive and effective treatment regimens for bladder cancer. In Scotland, Roche's Columvi has been endorsed by the Scottish Medicines Consortium for use in treating relapsed or refractory diffuse large B-cell lymphoma. This approval highlights the growing importance of bispecific antibodies in oncology, which can simultaneously engage two different antigens to enhance anti-tumor responses. Such innovations underscore the ongoing transformation of cancer treatment through combination therapies. Across the Atlantic, Health Canada has approved Clinuvel's Scenesse for erythropoietic protoporphyria (EPP), a rare condition causing extreme light sensitivity. Scenesse acts as a melanocortin receptor agonist, offering photoprotection and improving quality of life for those affected by this debilitating disorder. On the business front, Bayer's strategic partnership with Apollo has secured a €3 billion equity deal for its long-acting reversible contraceptives business. This move underscores a growing emphasis on women's health and contraceptive innovation. Likewise, CMS and Insilico's collaboration aims to harness artificial intelligence for CNS drug discovery, promising to accelerate drug development through AI-driven target identification. Clinical trials continue to reveal promising developments. Eisai's Etalanetug is showing potential in reducing tau tangle biomarkers in dominantly inherited Alzheimer's disease. Similarly, Eisai and BioArctic's Leqembi subcutaneous autoinjector demonstrates comparable efficacy to its intravenous counterpart, potentially improving compliance and accessibility for early Alzheimer's patients through less invasive administration methods. Financially, Apnimed is planning an IPO to support its sleep apnea pill's commercial launch, while Velogene Biotechnology has secured Series A funding to advance its gene-editing platform. These financial activities highlight ongoing investments in innovative solutions aimed at addressing unmet clinical needs. Yet, challenges persist as well. The FDA has rejected Hengrui and Elevar Therapeutics' combination treatment for hepatocellular carcinoma for a third time, emphasizing the difficulties of meeting regulatory standards and demonstrating efficacy. Additionally, Germany's new healthcare cost-saving law has doubled pharmaceutical rebate rates, sparking industry concern over potential impacts on profitability and innovation investment. The regulatory landscape continues to evolve with the FDA proposing streamlined registration processes under the "hub-and-spoke" model to enhance transparency and security within supply chains. Meanwhile, recent FDA transparency actions have led to the release of 14 drug rejection letters, underscoring ongoing challenges in securing approvals due to stringent regulatory requirements. Geographically, emerging biotech hubs like Basel and Beijing are gaining prominence as global talent hotspots due to their conducive environments for research and development collaboration. These regions are becoming increasingly attractive for biopharmaceutical innovation. Amid fierce competition in obesity management solutions, Lilly's launch of its oral GLP-1 receptor agonist Foundayo faces stiff competition from Novo Nordisk's Wegovy pill. The race reflects broader trends toward developing patient-centric therapies that offer convenience alongside therapeutic efficacy. Intellectual property strategies are also evolving as companies employ new patent tactics to maintain competitive advantages in crowded markets. Safety remains a top priority as exemplified by Lupin Pharmaceuticals' recall of contaminated eye drops, highlighting ongoing challenges in ensuring product safety. Lastly, advancements in wearable technology offer promising improvements in patient care; however, integration into clinical practice is met with infrastructural hurdles—a sentiment echoed by healthcare professionals surveyed by the AMA. Overall, these developments paint a complex picture of scientific innovation intersecting with regulatory evolution and strategic industry adaptations aimed at enhancing patient outcomes while navigating economic pressures. As the industry evolves, stakeholders must remain vigilant and adaptable to seize opportunities and address challenges effectively.Support the show

In March, China became the first country to approve an invasive brain-computer interface beyond clinical trials. The implant, called NEO, is now available to some patients with limb paralysis due to a spinal cord injury. Ira talks with Wired staff writer Emily Mullin about the significance of this milestone. Plus, brain implants aren't the only development: China's entire biotech industry has skyrocketed in recent years. A decade ago, about 8% of new drug molecules were discovered in China. Now it's over 40%. And more clinical trials are now being conducted there than in the U.S. or Europe. Ira talks with health policy researcher So-Yeon Kang, who's been following the Chinese pharma industry's meteoric rise. Guests: Emily Mullin is a staff writer at Wired.  Dr. So-Yeon Kang is an Assistant Professor of Health Management and Policy at Georgetown University.  Other episodes you may enjoy: Advances In Brain-Computer Interfaces For People With Paralysis How China Is Driving Down Electricity Costs With Renewables Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We love to hear from our listeners. Send us a message. On the Business of Biotech this week, industry veteran Dr. Jeremy Levin, Founder, Chairman, and former CEO at Ovid Therapeutics, sits down alongside the 2026 BIO Convention to talk about why public distrust and politicized institutions are putting the scientific enterprise at risk. We dig into what biotech leaders owe patients and the public, how innovation and capital can migrate out of the U.S., and what it takes to build biotech companies that last. Dr. Levin talks about his recently published book, Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust, what he learned during the writing process, and offers advice for first-time biotech CEOs.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative updates and strategic shifts within the industry, reflecting both remarkable progress and inherent challenges. Sanofi's recent achievement marks a significant milestone in oncology with the FDA approval of Sarclisa Escena (isatuximab) as the first on-body injector for multiple myeloma treatment. This monoclonal antibody, targeting CD38, offers a novel subcutaneous delivery method, simplifying administration and potentially enhancing patient compliance by reducing the need for frequent clinic visits. This aligns with the industry's ongoing shift towards patient-friendly drug delivery systems, emphasizing convenience without compromising efficacy. In another promising development, GSK and Hansoh Pharmaceutical have reported positive results from their Phase 3 trial evaluating risvutatug rezetecan for small cell lung cancer. This antibody-drug conjugate, targeting B7-H3, has shown potential when combined with chemotherapy to extend patient survival. Given the aggressive nature of small cell lung cancer and limited treatment options, these findings underscore the potential of targeted therapies to improve clinical outcomes significantly. Forte Biosciences' FB102 also takes a spotlight in clinical advancements. In its Phase 1b trial for vitiligo, FB102 demonstrated a 45.8% placebo-adjusted benefit. This monoclonal antibody works by modulating immune responses through the IL-15 pathway via CD122, offering new hope for patients with this challenging autoimmune condition. On the regulatory front, ARPA-H's commitment of up to $160 million towards developing personalized genetic medicines for rare diseases is noteworthy. This investment is set to accelerate innovations in gene therapy and personalized medicine platforms. Such advancements promise to revolutionize pediatric care and extend beyond by tailoring treatments to individual genetic profiles, enhancing efficacy while minimizing adverse effects. Strategic collaborations continue to reshape the industry landscape. Rani Therapeutics' partnership with PegBio aims at advancing oral delivery systems for obesity and metabolic diseases. Similarly, Simcere Pharmaceutical's collaboration with Schrödinger leverages AI-driven drug discovery efforts. These alliances highlight an increased reliance on computational platforms to streamline therapeutic development processes. From a financial perspective, Mesoblast Limited reports substantial revenue from its cell therapy product Ryoncil, signaling strong commercial viability for cell-based treatments targeting rare diseases. Additionally, Cue Biopharma's successful $50 million fundraising underscores investor confidence in advancing therapies for immunological disorders. However, not all news is positive. Roche has decided to halt two programs targeting Huntington's disease due to inadequate efficacy and safety concerns. This decision reflects the complexities involved in developing effective treatments for neurological disorders—a field fraught with scientific challenges yet rich with potential rewards. In market dynamics, McKinsey's report advocates for a structural redesign of biopharmaceutical R&D to fully leverage AI's capabilities. This recommendation resonates with current industry trends focusing on strategic innovation to maximize efficiency and discovery potential. The FDA's third rejection of Hengrui Pharma and Elevar Therapeutics' combination therapy for liver cancer underscores the rigorous scrutiny such treatments face despite their promise in addressing complex cancers. In contrast, BioNTech's preparation to launch its HER2 antibody-drug conjugate (ADC) signifies its strategic pivot back towards oncology after mRNA vaccine successes. Bayer's decision to sell a minority stake in its contraceptives business demonstrates how companies are strategically realigning portfolios to focus on core areas while securing funding for innovation. This move reflects broader trends within pharma as companies navigate financial landscapes to support long-term research goals. Amid these developments, regulatory environments continue evolving. NICE's stance against future Lumakras reimbursement in the UK highlights ongoing challenges in balancing cost-effectiveness with access to innovative therapies. Meanwhile, ARPA-H's significant funding allocation signals robust governmental support for advancing precision medicine within genetic therapies. In conclusion, today's updates reveal an industry characterized by a relentless pursuit of innovation amidst complex regulatory landscapes. As companies navigate these dynamics through strategic collaborations and scientific breakthroughs, their efforts hold promise for enhancing patient care across diverse therapeutic areas globally. Stay tuned as we continue to track these exciting developments shaping the future of pharmaceuticals and biotechnology. Thank you for tuning into Pharma Daily—your go-to source for up-to-date insights from the world of pharmaceuticals and biotechnology.Support the show

How can a company have the right numbers and still reach the wrong strategic conclusion?In 2017, Volkswagen's chief executive mocked Tesla as one of the “world champions of big announcements.” At the time, Volkswagen sold roughly eleven million cars a year, while Tesla sold fewer than eighty thousand. The facts supported the criticism, but the conclusion missed the change already underway.That moment explains why Elon Musk remains worth studying.Most public discussion focuses on his personality, political views, wealth, or communication style. This episode takes a different approach and examines the methods that allowed him to enter industries dominated by governments and large corporations, pursue ideas that initially appeared uneconomic, and force entire markets to reconsider what could be built.The starting point is Eric Jorgenson's The Book of Elon, which brings together more than two decades of Musk's interviews, speeches, podcasts, and public writing. Jorgenson has already done the first stage of the work by reducing a vast archive to the statements that best explain how Musk thinks about purpose, engineering, talent, production, and company building.Because the book is itself a quote summary, I treated it as raw material rather than as a conventional biography.I selected seven recurring principles and tested them against more than 25 years of my own company-building experience. That includes six years in public-market M&A and two decades building biopharma and medtech companies from Series A toward IPO across more than seven company journeys. I also draw on several Musk biographies, years of long-form podcast interviews, and his public writing on X.The result is not another biography, and it is not an argument that every founder should copy Elon Musk.It is a practical framework for founders, CEOs, board members, investors, scientists, and senior executives who build or finance hard companies.The central question is straightforward:What can you copy from Elon Musk without copying the personality?The episode examines why utility matters more than glory, why important companies often have to build before market permission arrives, and how first-principles thinking exposes opportunities that remain hidden when an industry accepts precedent as fact. It also explains why strong teams delete complexity before they automate it, why positive-sum founders enlarge markets instead of fighting over a fixed share, and why talent density matters more than headcount.The final principle brings everything together. A prototype may attract attention and capital, but the company only creates lasting value when it can produce, learn, improve, and scale faster than its competitors.This distinction matters in life sciences and deep tech, where strong science can still fail during translation. A molecule may work while manufacturing, clinical execution, reimbursement, financing, or commercialization remain underdeveloped. The same problem appears in industrial technology, energy, AI, and robotics, where an impressive demonstration can conceal a production system that will never support scale.Three statements from the book frame the discussion:“How many people you helped, and how much. That's the total utility.”“The most common mistake of smart engineers is to optimize a thing that should not exist.”“What really matters is the machine that builds the machines, the factory.”Taken together, the seven principles form a founder test.For investors, they provide a structured way to assess mission, judgment, cost discipline, team quality, and the ability to scale. For company builders, they offer practical questions that belong in financing discussions, board meetings, and leadership offsites.Are you building something useful enough to change customer behavior?Does the team reason from fundamental constraints, or does it repeat the industry's assumptions?Are you simplifying the company, or automating bureaucracy?Can the organization turn promising technology into a repeatable system that produces real customer value?Whatever your opinion of Elon Musk, dismissing the method because you dislike the man can become an expensive mistake. The personality remains optional, while the principles deserve serious examination.Choose one of the seven and bring it into your next board meeting.Chapters(00:00) Introduction: Why the market keeps underestimating Elon Musk(03:31) The Big Idea(08:13) Eric Jorgenson and why he is the right author(10:47) Lesson 1: Build for Utility, Not Glory(16:39) Lesson 2: Missionary Courage Beats Market Permission(21:28) Lesson 3: First Principles Reveal Hidden Upside(25:59) Lesson 4: The Algorithm: Delete Before You Optimize(31:09) Lesson 5: Grow the Pie: Reject Zero-Sum Thinking(35:57) Lesson 6: Talent Density Is the Company(40:54) Lesson 7: Production and Speed Are the Real Moat(45:46) The Seven Practical Takeaways(51:55) Personal Reflection, Critique, and ClosingSend us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now.Support the showJoin the Podcast Newsletter: Link

On this edition of The Federalist Radio Hour, Executive Chairman of Ovid Therapeutics Dr. Jeremy Levin joins Federalist Senior Elections Correspondent Matt Kittle to discuss how the biotech industry is essential for American healthcare and security, and how China has strategically advanced its biotech industry to overtake the United States'. They also discuss the distrust Americans have in health institutions and how Covid politics invaded scientific institutions to enforce an agenda.You can find Dr. Levin's new book, Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust, here.The Federalist Foundation is a nonprofit, and we depend entirely on our listeners and readers — not corporations. If you value fearless, independent journalism, please consider a tax-deductible gift today at TheFederalist.com/donate. Your support keeps us going.

On this edition of The Federalist Radio Hour, Executive Chairman of Ovid Therapeutics Dr. Jeremy Levin joins Federalist Senior Elections Correspondent Matt Kittle to discuss how the biotech industry is essential for American healthcare and security, and how China has strategically advanced its biotech industry to overtake the United States'. They also discuss the distrust Americans […]

I hope you guys enjoy my podcast with @Seedy19 (from X). Seedy is a full-time biotech investor. He generated a 35x on his entire portfolio last year. Not just one stock, his entire portfolio. The crazy part? He did it buying mostly common stocks. Biotech stocks, of course. But common stocks nonetheless!We spend an hour diving into Seedy's process, how he identifies new ideas, researches positions, weighs probabilities, and separates the real companies from the shams. I loved recording this episode. PLEASE NOTE NONE OF THIS IS INVESTMENT ADVICE. IT IS PURELY EDUCATIONAL/ENTERTAINMENT PURPOSES ONLY. DO NOT TRADE ANY OF THESE SECURITIES WITHOUT CONSULTING A LICENSED PROFESSIONAL. YOU ARE AN IDIOT FOR TRYING TO TRADE BIOTECH.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and challenges shaping the landscape of these dynamic sectors. Starting with Ipsen's Dysport, which has made notable strides in its Phase 3 trials for migraine prevention. The trials covered both episodic and chronic conditions, marking a first in the neurotoxin market. Dysport's success positions it as a formidable competitor to AbbVie's Botox, expanding therapeutic options for individuals battling migraine disorders. This achievement showcases the potential efficacy of botulinum toxin-based therapies in neurology and pain management, offering promising new avenues for patient care. In regulatory news, Boehringer Ingelheim has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for Jascayd, a small molecule PDE4B inhibitor with antifibrotic properties. This approval marks a significant milestone in the treatment of idiopathic and progressive pulmonary fibrosis. Jascayd's addition to the therapeutic arsenal offers new hope for managing this debilitating condition, emphasizing the ongoing efforts to improve patient outcomes through innovative treatments. The arena of business development sees HanChorBio partnering with InxMed to advance oncology research. By combining HCB101 with FAK inhibitors and FAP-targeted ADCs, this collaboration aims to leverage antibody and small molecule drug discovery techniques. The goal is to develop innovative cancer treatments that could redefine therapeutic approaches in oncology. Keenova Therapeutics has also reported success with Xiaflex for plantar fibromatosis. This enzyme injection therapy offers a novel approach by targeting collagen, thus providing an innovative solution for musculoskeletal conditions. Similarly, Fate Therapeutics' FT819, an off-the-shelf CAR-T therapy, has shown early promise in tackling treatment-resistant systemic sclerosis, underscoring the potential of cell therapies beyond oncology. Meanwhile, MindRank's successful Series B funding round of $52 million highlights the growing role of AI platforms in drug discovery. The funding will propel its AI-discovered oral GLP-1 obesity pill into Phase III trials, exemplifying how technology-driven solutions are gaining traction in addressing metabolic diseases like obesity. On the regulatory front, Saol Therapeutics has resubmitted SL1009 (DCA) to the FDA for pyruvate dehydrogenase complex deficiency. This submission underscores ongoing efforts to address rare metabolic disorders using small molecule therapies. Additionally, Sanofi's concessions to the EU regarding flu vaccine marketing illustrate the complexities of competitive dynamics and regulatory scrutiny within the vaccine market. However, not all developments are favorable. AstraZeneca and Ionis Pharmaceuticals faced a setback as their drug Wainua failed its Phase 3 trial for transthyretin-mediated amyloid cardiomyopathy. This outcome highlights the challenges inherent in developing effective treatments for complex cardiovascular conditions. Meanwhile, regulatory processes remain contentious as the FDA pauses its release of complete response letters amid debates over proprietary information disclosures. In another noteworthy development, GSK has terminated its $2.2 billion collaboration with Alector after underwhelming results from Alzheimer's drug trials. This decision highlights both financial implications and strategic shifts as companies reassess risk tolerance in neurodegenerative disease research. Conversely, Roche's success with its KRAS G12C inhibitor divarasib in Phase 3 lung cancer trials underscores the promise of precision medicine. Divarasib outperformed competitors Amgen's Lumakras and Bristol Myers Squibb's Krazati, positioning Roche to potentially redefine standards of care based on genetic profiles. In a move reflecting industry trends towards collaboration and innovation risk-sharing models, AstraZeneca has partnered with Sino Biopharmaceutical on respiratory disease research. This strategic alliance represents a substantial investment aimed at expanding AstraZeneca's pipeline in respiratory therapeutics. Lastly, amidst these developments, psychedelic drugs are experiencing a renaissance in psychiatric care. Companies like Compass Pathways are pioneering clinical validation for their use in treating depression, signaling a potential paradigm shift from traditional SSRIs to newer therapeutic classes pending safety and efficacy data. Overall, these stories illustrate a dynamic interplay of scientific progress and regulatory navigation within the pharmaceutical and biotech sectors. While challenges persist—particularly in neurodegenerative disease treatment—the breakthroughs in oncology and metabolic disorder therapeutics offer hopeful prospects for improving patient care. As these industries continue evolving, integrating advanced technologies such as AI will likely play a pivotal role in shaping future therapeutic landscapes.Support the show

By the time the paper hit version 71, Dr. Nirosha Murugan had already done the hard part. The data were real. The experiment had worked. A team of researchers had used a wearable bioreactor to trigger limb regeneration in frogs, a result with obvious implications for regenerative medicine. But the science still wasn't getting over the line. The problem wasn't the work. It was the translation.On this episode of Standard Deviation, host Oliver Bogler talks with Dr. Nirosha Murugan, a biophysicist and Tier II Canada Research Chair in Tissue Biophysics at Wilfrid Laurier University, about what happens when a scientist working at the edges of quantum biology, bioelectricity, and tissue regeneration runs headfirst into the unwritten rules of academic publishing. Murugan's research asks biologists to think beyond molecules and chemistry alone, and to consider the physical signals, electromagnetic fields, and invisible forces that shape development and healing. It is ambitious science. It is also exactly the kind of work that can make gatekeepers nervous.Bogler follows Murugan through the less glamorous part of discovery: the hidden curriculum of getting a paper published, securing scientific credibility, and learning that data do not simply “speak for themselves.” Murugan describes how jargon buried the pitch of her own work, how a lack of editorial support left her at a disadvantage, and how the JEDI program at the Life Science Editors Foundation paired her with a former journal editor who taught her how to structure a manuscript, write a cover letter, and survive peer review.The result was publication in Science Advances, but the larger story is about power. Who gets taught the rules of biomedical research. Who has access to grant writers, editors, and institutional polish. Who is left to brute-force their way through the maze. And how one scientist, having finally found the map, now makes sure her own trainees do not have to learn it the hard way.RELATED LINKSDr. Nirosha Murugan⁠Wilfrid Laurier University⁠Life Science Editors Foundation⁠JEDI Program⁠Science Advances paper on limb regeneration⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Bestselling author Steven Kotler explores how advances in artificial intelligence, robotics and biotechnology are reshaping humanity and what it will take to thrive in an era of exponential change.

Deze aflevering hebben we het over banken! Over ABN Amro en over Unicredit (en daarmee automatisch over Commerzbank). ABN wordt hard op de vingers getikt, Unicredit kan gewoon zijn gang gaan. ABN moet een boete betalen, Unicredit blijft juist miljoenen uitgeven aan een overname waar de andere bank niet op zit te wachten. We hebben het over die boete van ABN. Die is er omdat ze (alweer) steken laten vallen met de controle op witwassen. Er zijn erge fouten gemaakt, zegt toezichthouder DNB. Alleen beleggers maken zich er totaal niet druk om. Is dat terecht? Hoor je ook over Unicredit. Dat heeft inmiddels 48 procent van Commerzbank in handen. Waarmee ze in feite alle macht hebben op aandeelhoudersvergaderingen. We kijken wanneer de overname er is. Ook of we nu een overnamegolf in bankenland kunnen verwachten. Verder gaat het ook nog over het massaontslag bij Volkswagen. Het was vandaag erop of eronder voor de ceo. Hij moet dat immense ontslag proberen te verkopen bij de kritische raad van commissarissen. Te gast: Jean Paul van Oudheusden van Markets are Everywhere BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Je hoort hem ook in de BNR-podcast Moerdijk: dorp van de rekening. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie.See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping our industry, starting with a significant regulatory milestone. Vera Therapeutics recently achieved FDA accelerated approval for Trutakna, a groundbreaking treatment for IgA nephropathy. This approval not only provides new hope for patients suffering from this chronic kidney disease but also highlights the innovative approach targeting APRIL and BAFF pathways, crucial in immune system regulation. The drug's accelerated approval is particularly noteworthy as it offers earlier access to promising therapies while further trials solidify its benefits. This positions Vera Therapeutics against industry giants like Novartis and Otsuka in nephrology therapeutics, highlighting the competitive landscape within this sector. The FDA's expedited pathways are increasingly facilitating quicker access to life-saving drugs, aligning regulatory processes with scientific advancements to address unmet medical needs. The spotlight on fusion proteins in tackling autoimmune and renal disorders could signal a broader trend in therapeutic development. In parallel, AstraZeneca has made waves by entering into a major licensing agreement with Sino Biopharmaceutical for their COPD candidate TQC3721. This $1.9 billion deal, with a $200 million upfront payment, exemplifies how global collaborations are becoming pivotal in expanding market reach. By focusing on respiratory diseases, AstraZeneca is strategically positioning itself to enhance treatment options for COPD patients worldwide, reflecting an industry-wide movement towards leveraging regional expertise in drug commercialization. Meanwhile, Evonik's $100 million investment in an Indiana API manufacturing plant marks a strategic effort to bolster domestic production capacities post-pandemic. This investment underscores the rising demand for Contract Development and Manufacturing Organization (CDMO) services, emphasizing supply chain resilience—an increasingly critical factor as biotech firms seek reliable production partners. On the clinical trial front, Satellos Bioscience has reported promising Phase 1 data for SAT-3247, its Duchenne muscular dystrophy candidate. This AAK1 inhibitor demonstrates potential in promoting muscle regeneration, a development that could significantly alter treatment paradigms for this progressive neuromuscular disorder. If further trials confirm these findings, it could revolutionize therapeutic approaches for rare diseases. Financially, Leo Cancer Care's recent $65 million Series D funding is set to advance its upright radiotherapy treatment system. Such innovations aim to improve precision and outcomes in cancer therapy, at the intersection of technology and patient care. Similarly, MeiraGTx's securing of up to $400 million from Oberland Capital underlines ongoing confidence in gene therapies targeting rare ophthalmological conditions. Strategic maneuvers continue to reshape industry landscapes with mergers like that of Caidya and Simbec-Orion forming a global CRO platform aimed at enhancing research capabilities across oncology and rare diseases. Such consolidations reflect broader trends towards operational efficiencies and scaling research capabilities globally. Amidst these developments, quality control remains paramount as evidenced by Amgen's recall of its heart failure drug due to quality concerns. Such challenges reiterate the importance of stringent quality assurance throughout production processes in safeguarding patient safety. Vertex's acquisition of Crinetics for $10 billion marks another strategic expansion into "white space blockbuster opportunities," illustrating how M&A activity is driving companies to bolster pipelines and capitalize on emerging scientific advancements. These developments collectively underscore the dynamic nature of the pharmaceutical and biotech industries as they navigate complex regulatory landscapes, financial recalibrations, and scientific breakthroughs. As companies strive towards more effective and accessible treatments across various therapeutic areas, their ability to adapt to these challenges remains crucial in shaping the future of healthcare delivery. Thank you for tuning into Pharma Daily. Stay informed with us as we continue to bring you the latest insights from the world of pharmaceuticals and biotechnology.Support the show

People are living longer than ever before and the science helping us live healthier for longer is advancing at a rapid pace. From AI-powered drug discovery and personalised medicine to GLP-1s and the longevity economy, this episode explores the trends reshaping healthcare, the companies leading the charge, and how investors can gain exposure to one of the world's fastest-growing industries.In this episode:00:00 – Why longevity is becoming a major investment theme03:16 – The $3.5 trillion biotech opportunity & the rise of the longevity economy07:58 – AI, peptides & personalised medicine driving medical breakthroughs14:56 – The risks: regulation, clinical trial failures & tariffs17:47 – Partner message from ANZ Business Start Right19:22 – The biggest opportunities in biotech over the next decade20:25 – The companies leading the biotech revolution27:13 – ETFs and how to invest in Biotech & LongevityStocks & ETFs Mentioned: CSL (ASX: CSL), Pfizer (NYSE: PFE), Merck (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Roche, AstraZeneca (LSE: AZN), AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), Vertex Pharmaceuticals (NASDAQ: VRTX), Regeneron Pharmaceuticals (NASDAQ: REGN), Moderna (NASDAQ: MRNA), BioNTech (NASDAQ: BNTX), Unity Biotechnology (NASDAQ: UBX), BioAge Labs (NASDAQ: BIOA), Recursion Pharmaceuticals (NASDAQ: RXRX), ResMed (ASX: RMD), Cochlear (ASX: COH), Sonic Healthcare (ASX: SHL), Pro Medicus (ASX: PME), Telix Pharmaceuticals (ASX: TLX), Mesoblast (ASX: MSB), VanEck Global Healthcare Leaders ETF (ASX: HLTH), iShares Global Healthcare ETF (ASX: IXJ), Betashares Global Healthcare Currency Hedged ETF (ASX: DRUG), iShares U.S. Pharmaceuticals ETF, iShares Biotechnology ETF (NYSEARCA: IBB), SPDR S&P Biotech ETF (NYSEARCA: XBI), ARK Genomic Revolution ETF (BATS: ARKG), Range Cancer Therapeutics ETF (CANC)This episode ofThe Decade Ahead is brought to you by ANZ Business Start Right.———Want to get involved in the podcast? Record a voice note or send us a messageAnd come and join the conversation in the Equity Mates Facebook Discussion Group.———Want more Equity Mates? Across books, podcasts, video and email, however you want to learn about investing – we've got you covered.Keep up with the news moving markets with our daily newsletter and podcast (Apple | Spotify)We're particularly excited to share our latest show: Basis PointsListen to the podcast (Apple | Spotify)Watch on YouTubeRead the monthly email———Looking for some of our favourite research tools?Download our free Basics of ETF handbookOr our free 4-step stock checklistFind company information on TIKRResearch reports from Good ResearchTrack your portfolio with Sharesight———This podcast is intended for education and entertainment purposes only. Any advice is general advice and has not taken into account your personal financial circumstances. Before acting on general advice, you should consider if it is relevant to your needs. If unsure, speak to a financial professional. The host of this podcast and their guests may have positions in the companies mentioned. Equity Mates Media is part of the Betashares Group but maintains editorial independence and operates under Australian Financial Services licence 540697. Hosted on Acast. See acast.com/privacy for more information.

Where do scientific breakthroughs really begin, and how much space do we leave for curiosity, intuition, and creative thinking along the way?In this episode, host Elaine Hamm, PhD, is joined by Auni Williams, PhD, a postdoctoral scholar at Penn State University, for a thoughtful and refreshing conversation about “night science.” Together, they explore the idea that behind every polished grant, publication, or protocol is a messier, more human process driven by curiosity, imagination, and the freedom to explore unconventional ideas. From historical examples of scientific breakthroughs to personal stories from the lab, this episode invites listeners to rethink how discovery really happens.In this episode, you'll learn:What “night science” is and why embracing early, unpolished ideas is critical for innovation and discovery.How modern research culture can unintentionally suppress creativity – and what institutions and leaders can do to protect exploratory thinking.Why communicating science as a human, curiosity-driven process is essential for engaging both scientists and the public.Tune in to learn how making space for curiosity, creativity, and night science can reignite passion for research and lead to the next generation of scientific breakthroughs.Links:Connect with Auni Williams, PhD, and learn more about Penn State University.Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine.Learn more about François Jacob, Barry Marshall, August Kekulé, Operation Everest, American Heart Association Funding, and Cormac McCarthy's essay.Listen to our previous episode with Walter Isaacson.Connect with Ian McLachlan, BIO from the BAYOU producer.Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that showcase the dynamic nature of this industry. In a landmark development, Vertex Pharmaceuticals has made headlines with its acquisition of Crinetics Pharmaceuticals for a staggering $10 billion. This move marks Vertex's strategic expansion into the endocrine disease sector, a significant shift from its traditional focus on cystic fibrosis. Crinetics' innovative approach to treating rare endocrine disorders will allow Vertex to address unmet needs in this area, highlighting a broader industry trend where mergers and acquisitions serve as key strategies for adapting to the evolving scientific landscape and patient demands. While Vertex makes bold moves, Kalohexis is preparing for a confidential initial public offering (IPO), focusing on treatments based on the melanocortin system for obesity and cancer cachexia. The melanocortin system is crucial in regulating energy homeostasis and inflammation, making it a promising target for therapeutic interventions. This development underscores the growing interest in peptide-based therapies and innovative scientific approaches to address complex metabolic disorders, further emphasizing the industry's shift towards tackling significant health challenges such as obesity. Clinical trials continue to be at the forefront of medical advancements. Compass Pathways has reported promising Phase III trial results for COMP360, its psilocybin-based therapy for treatment-resistant depression. These findings indicate a potential breakthrough in psychedelic therapy, offering new hope for patients who haven't benefited from existing antidepressant treatments. The exploration of psychedelics in mental health treatment represents a paradigm shift that could introduce novel therapeutic options and significantly impact patient care. Turning to regulatory news, AbbVie's Tepkinly (epcoritamab) has received European Commission approval for treating relapsed or refractory follicular lymphoma. This approval is based on robust Phase III data, underscoring the potential of bispecific antibodies as effective cancer therapies. Similarly, PharmaEssentia's Besremi (ropeginterferon alfa-2b) has obtained Health Canada approval for polycythemia vera treatment, highlighting the continued relevance of protein and interferon therapies in managing myeloproliferative neoplasms. In business development news, Novo Nordisk and Vivani Medical have partnered to develop an ultra-long-acting semaglutide implant for chronic weight management. This collaboration showcases advancements in drug delivery systems aimed at improving patient compliance and therapeutic outcomes. Meanwhile, Boehringer Ingelheim's licensing agreement with Prime Vector Technologies involves harnessing viral vectors for cancer vaccine development, emphasizing ongoing efforts to innovate within oncology. Despite these advancements, challenges persist within the industry. Notably, Bristol Myers Squibb's Krazati (adagrasib) failed its Phase III confirmatory trial in metastatic colorectal cancer with KRAS G12C mutations. This outcome highlights the complexities involved in developing targeted cancer therapies and underscores the need for continued innovation and exploration of combination treatments. The financial landscape also reflects strategic adjustments with Regeneron Pharmaceuticals reporting a $127 million charge impacting its earnings due to an in-process research and development expense. Additionally, Novartis is undergoing organizational restructuring with workforce reductions aimed at cost management within large pharmaceutical enterprises. On another front, China's recent approval of the world's first CAR-T therapy for solid tumors marks a significant leap forward from its traditional success in hematological malignancies. This development highlights the potential for CAR-T therapies to address complex challenges posed by solid tumors and could have profound implications for global cancer treatment paradigms. AstraZeneca's partnership with CSPC Pharmaceutical represents another strategic collaboration aimed at co-developing kidney disease drugs, reflecting Western pharmaceutical companies' efforts to leverage Chinese biotechnological capabilities. As companies navigate these complexities through strategic acquisitions, partnerships, and groundbreaking research, their ability to adapt will be crucial in shaping future patient care and therapeutic landscapes. The pharmaceutical and biotech industries remain at the forefront of scientific advancement, continually seeking solutions to complex medical needs while adapting to an ever-evolving global landscape.Support the show

Dr. Jess Peatross trained in conventional medicine and worked as a hospitalist before she started questioning why so many chronically ill patients kept getting worse inside the healthcare system she trusted. Her perspective carries weight because she spent years following every protocol exactly as taught before walking away from hospital medicine entirely.Raised in Huntington, West Virginia during the opioid crisis, she entered medicine believing the system existed to heal people. Instead, she found hospitals driven by billing codes, liability management, and pharmaceutical dependence while patients with chronic illness, autoimmune disease, mold exposure, and chronic pain cycled endlessly through appointments and prescriptions.Dr. Peatross explains what pushed her toward functional medicine, cannabis therapy, and prevention focused care after watching patients improve only after leaving conventional treatment pipelines behind. The conversation tackles physician burnout, chronic illness stigma, healthcare incentives, and the growing collapse of trust between patients and institutions.The discussion also moves into supplements, environmental toxins, ultra processed food, and the uncomfortable economics behind keeping people permanently sick but continuously billable. Dr. Peatross describes the professional backlash that comes with challenging medical orthodoxy while Matthew connects her experience to the broader erosion of public trust across American healthcare.Together they unpack what happens when patients stop believing the system can help them and start searching elsewhere for answers.RELATED LINKSDr. Jess PeatrossInstagramMarshall UniversityBrave New WeedFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Hoffman continues his conversation with physician and molecular biologist Dr. Adrian Woolfson, co-founder of Genyro, a biotechnology company specializing in synthetic genome design and construction, and author of “On the Future of Species: Authoring Life by Means of Artificial Biological Intelligence.”

AI and Generative Biology: Authoring Life, Redesigning Healthcare, and Building Guardrails: Physician and molecular biologist Dr. Adrian Woolfson, co-founder of Genyro, a biotechnology company specializing in synthetic genome design and construction, and author of “On the Future of Species: Authoring Life by Means of Artificial Biological Intelligence,” discusses the convergence of AI with synthetic/generative biology that could make biology programmable and enable genome design and construction beyond traditional gene editing. Woolfson argues that the technology is morally neutral but is arriving rapidly and requires public awareness, governance, and guardrails due to risks, including misuse by authoritarian regimes and biological warfare. He discusses evolution's trade-offs and why he favors limiting human applications to curing disease and extending healthy longevity, while opposing germline modification; he explains germline vs somatic editing and cites the flawed, unethical case of a Chinese scientist attempting inherited HIV resistance. They examine sickle cell disease cures costing $2–$3 million, scalability issues, and trade-offs like malaria protection, and highlight non-medical benefits such as engineered crops, biomaterials, desalination, and DNA-based information storage.

We walk through July's biggest life and bioethics stories and ask how Christians can speak with clarity when the culture treats some lives as disposable. We keep returning to one anchor: every human life bears God's image, so neither disability, suffering, nor social pressure gives us authority over life and death. • How disability gets framed as tragedy or as a “glitch” • IVF and how the church should lead the conversation• Assisted Suicide and the habit of avoiding the actual topic • Gene editing and the Biotech Barbie• Gallup polling on moral acceptability and how language hides moral nuance Please consider subscribing to this podcast, giving us a review wherever you access it, and sharing it with friends. Support the showThe ministry of Christian Life Resources promotes the sanctity of life and reaches hearts with the Gospel. We invite you to learn more about the work we're doing: https://christianliferesources.com/When the world feels confusing, heavy, and loud, where do you find something solid to stand on? Rooted by the River is a one-day pro-life, Christian conference designed to anchor you in God's Word and equip you to face some of today's hardest issues. Don't miss presentations on coping, sexual shame, AI, and better conversations about abortion. Plus a powerful interview with an abortion survivor! You'll be strengthened to live and speak with courageous, Christ-centered hope right where God has placed you. Register today: https://christianliferesources.com/get-involved/events/2026-conference

Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode of the BioCentury This Week podcast, BioCentury's analysts discuss how the deal fits with the Swiss pharma's cancer toolkit.The analysts then discuss MHRA CEO Lawrence Tallon's Guest Commentary in BioCentury on making regulation a catalyst for U.K. life sciences and why the primary defeat of Rep. Diana DeGette (D-Colo.) is a setback for FDA reforms. They also assess how single-cell Parkinson's atlases reveal neuronal and glial disruptions in specific regions and stages, and the thin evidence underpinning Congress' probe of China trial consent. This episode of the BioCentury This Week podcast has been brought to you by CBRE.View full story: https://www.biocentury.com/article/660033#ADC #BiotechMA #ParkinsonsDisease #FDA #ChinaBiotech00:01 - Sponsor Message: CBRE01:15 - Novartis Buying Myricx08:01 - U.K. Regulation14:44 - DeGette & FDA Reform21:51 - Parkinson's Atlas Insights29:39 - China Trials ProbeTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Bihua, CEO and PM of Cormorant Asset Management ($2.5B AUM), explains how she evaluates science, risk, and opportunity across both public and private biotech markets. She shares how investors can separate signal from hype, underwrite uncertainty in drug development, and identify the breakthroughs most likely to shape the future of medicine.-This podcast/webcast is provided for informational purposes only and should not be considered legal, tax, investment, or business advice. It is not a solicitation, recommendation, or endorsement. All opinions expressed by participants are their own and do not necessarily reflect the views of the Evoke Advisors Division of MAI Capital Management, LLC ("Evoke”), its affiliates, or any companies mentioned. Information shared has not been independently verified by MAI or its affiliates. MAI Capital Management, LLC (“MAI”) is registered with the U.S. Securities and Exchange Commission ("SEC"), which does not imply any particular level of skill or training.Certain information contained herein has been obtained from third party sources and such information has not been independently verified. No representation, warranty, or undertaking, expressed or implied, is given to the accuracy or completeness of such information by any person.While such sources are believed to be reliable, Evoke does not assume any responsibility for the accuracy or completeness of such information. Evoke does not undertake any obligation to update the information contained herein as of any future date.The content is intended for a general audience and does not constitute a recommendation to buy or sell securities or adopt any investment strategy. Any examples or scenarios discussed are illustrative only, involve risks and uncertainties, and do not guarantee future results. Non-traditional assets carry significant risks and may not be suitable for all investors. Decisions should be based on individual objectives, risk tolerance, and circumstances.Statements herein are general and may not reflect an individual's or entity's specific circumstances or applicable laws, which vary by jurisdiction. Further, speakers' views are personal and may differ from Evoke and MAI recommendations and are not specific investment advice; and do not consider client objectives, risk tolerance, and diversification. Guests may have current or past relationships with Evoke and MAI, its affiliates, or the host, including as clients, service providers, or business partners. Participation does not constitute an endorsement or testimonial. No compensation has been paid or received for guest participation unless disclosed. MAI and its affiliates may have business relationships with entities mentioned in this podcast, which could create potential conflicts of interest. These relationships may include advisory services, investment management, or other arrangements. MAI seeks to manage such conflicts consistent with its fiduciary obligations and policies.(As of December 22, 2025)

On this week's Tech Nation, Moira speaks with Physician and Entrepreneur, Dr. Jeremy Levin, about the big picture of biotech - and how it affects us all. They discuss the challenges facing the industry today: from global pandemics to funding cuts, to politics influencing innovation - and what it means for the future of health in the US. Dr. Levin's book is, “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust”

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The first quarter of 2026 has brought a wave of significant changes and advancements in the industry, marked by crucial regulatory updates, strategic acquisitions, and shifts in the competitive landscape. A pressing issue for many companies is the looming patent cliff for several branded biologics. This situation presents both challenges and opportunities for biosimilars in the U.S. market. The introduction of biosimilars for major products like AbbVie's Humira, Johnson & Johnson's Stelara, and Regeneron/Bayer's Eylea is shifting the narrative from slow adoption to a more competitive biosimilar market landscape. Vertex Pharmaceuticals has achieved a milestone with the FDA expanding the label for its gene therapy Casgevy, now approved for treating children as young as two with sickle cell disease or transfusion-dependent beta thalassemia. This expansion emphasizes the potential of gene therapies to revolutionize treatment options for younger patients suffering from these conditions. In a pivotal development, Novartis announced a significant acquisition of UK biotech Myricx. With an upfront payment of $1.1 billion and potential total value up to $1.5 billion, this acquisition is set to enhance Novartis' antibody-drug conjugate (ADC) pipeline by incorporating Myricx's novel payload technology and NMT inhibitor payloads. This move reflects Novartis' focus on precision oncology by improving ADC efficacy through targeting critical enzymatic pathways involved in tumorigenesis. Amgen faced a setback with a voluntary recall of approximately one million bottles of its heart medication Corlanor due to potential contamination, highlighting the critical importance of maintaining rigorous manufacturing quality control to ensure drug safety. The regulatory landscape continues to evolve, illustrated by Robert F. Kennedy Jr.'s Department of Health and Human Services revoking lingering COVID-19 emergency authorizations. This signals a transition towards post-pandemic normalcy and an evolving focus on pandemic preparedness frameworks. Sanofi's Genzyme unit in Ireland faced criticism after an FDA inspection linked to Altuviiio resulted in a Form 483 notice. This incident underscores ongoing challenges in maintaining compliance with stringent regulatory standards and emphasizes the importance of robust quality assurance mechanisms. Lonza is expanding its capacity for producing ADCs and enhancing its partnership with a large U.S. drugmaker, aligning with industry trends toward outsourcing complex biologics manufacturing amid growing demand for ADCs. Genentech is undergoing restructuring, resulting in 103 layoffs as part of a strategic rethink of its early development group. Despite these changes, Genentech entered a $490 million collaboration focused on breast cancer, demonstrating its commitment to innovation amid organizational shifts. AstraZeneca continued its collaborative efforts by signing a $1.7 billion kidney drug discovery pact with Chinese biotech CSPC Pharmaceutical. This partnership emphasizes AstraZeneca's strategy to leverage global collaborations to accelerate drug discovery and development efforts. Scribe Therapeutics filed for an Initial Public Offering (IPO) to advance its CRISPR-based gene editing technologies targeting cardiovascular diseases at a genetic level, highlighting an ongoing shift toward personalized medicine. Celea Therapeutics raised $180 million in venture funding to advance Deupirfenidone into late-stage clinical trials for Idiopathic Pulmonary Fibrosis (IPF), signaling confidence in its therapeutic potential amid ongoing investment trends targeting rare diseases. The Medicines and Healthcare products Regulatory Agency expanded approval for Novo Nordisk's Wegovy for Metabolic-Associated Steatohepatitis with moderate-to-advanced liver fibrosis. This expansion represents significant progress given MASH's rising prevalence and progression risks. BridgeBio's ATTRibute-CM study yielded promising results with Acoramidis offering kidney-protective benefits in transthyretin amyloidosis cardiomyopathy patients—a potential new approach managing this rare disease. Revolution Medicines reported encouraging data for its KRAS inhibitor Zoldonrasib in combination therapies targeting metastatic pancreatic ductal adenocarcinoma—offering new strategies against aggressive cancer types. Brii Bio's phase 2b trial results show promise for a combination therapy aimed at achieving a functional cure for chronic Hepatitis B Virus infection—offering hope for millions affected by this condition. Robust fundraising activities continue within biotech sectors as Monash University and Atisama Therapeutics secure funding from MRFF grants developing therapies targeting chronic lung diseases. Overall, these developments highlight dynamic transformations reshaping therapeutic landscapes through precision medicine approaches leveraging cutting-edge technologies promising improved patient care across various domains within pharmaceutical industries globally.Support the show

A changing macro backdrop is creating new opportunities across the equity market. Our CIO and Chief U.S. Equity Strategist Mike Wilson looks at what's driving the shift and where it may lead next.Read more insights from Morgan Stanley.----- Transcript ----- Welcome to Thoughts on the Market. I'm Mike Wilson, Morgan Stanley's CIO and Chief U.S. Equity Strategist. Today on the podcast I'll discuss why I think the broadening out in equity markets can continue. It's Monday, July 6th at 11:30 am in New York. So, let's get after it. Let's talk about a market dynamic that's becoming harder to ignore. The broadening trade is back, and it's gaining momentum partly because one of the most crowded areas of the market – Semiconductors – is finally starting to lose some of its own. To be clear, this doesn't mean the AI cycle is over. However, trends don't move in straight lines, and leadership can ebb and flow; especially if there are fundamental reasons supporting it. In fact, we've seen this happen several times already over the past couple of years with the hyperscalers and semiconductors ebbing and flowing. This is based on positioning, the rate of change on expectations for capex and the returns on that capex. Meanwhile, our broadening call goes back to last November. Back then, we argued the economy had entered a new expansion after the rolling recession ended in the April of 2025. That view was based on a classic early-cycle setup where revenue growth returns to companies that had become cost efficient. That is the definition of operating leverage and that always leads to better than expected earnings growth – the core differentiation to our original outlook this year. The market started to discount that broadening late last year and into early this year. Then, the Iran war interrupted it. Oil prices surged, and the bond market went from pricing Fed cuts to pricing hikes, and investors crowded back into the obvious AI capex winners – especially Semiconductors. That made sense for a while. The revisions in Semis were spectacular. But when earnings revisions breadth gets pressed against historical extremes, the question becomes less about whether the story is good and more about whether the rate of change can keep improving. That's a much higher bar. And over the past few weeks, the market seems to be asking that question with semiconductor stocks fading. The underperformance in the hyperscalers was probably the first signal. Semis depend on hyperscaler capex, so when the spenders start to lag the beneficiaries, that divergence can't last forever. It usually ends up reconciling with hyperscalers' tempering capex guidance or indicating they are more focused on getting a return on that investment. META's announcement last week that it would begin selling excess capacity to outside customers fits right into that discussion. It doesn't kill the AI buildout, but it does change the market's perception of how linear that buildout will be. What matters for investors is how they should trade it. First, the market should continue to broaden out. Second, we continue to favor Consumer Discretionary Goods, Transports, Regional Banks, and now Biotech as part of that rotation. Discretionary Goods remains the cleanest expression, in my view, because the wallet-share shift from services back to goods is underway, goods pricing is improving, oil prices have fallen, and earnings revisions are strengthening. Transports are also showing better revisions, and Regional Banks still benefit from the broader recovery, improving loan growth dynamics and our call for a re-steepening of the yield curve. Biotech deserves more attention here, too. It is also one of the most rate-sensitive areas of the market, and our work shows it has historically done very well in falling-rate regimes. If the market's policy expectations are too hawkish – and I think they are – then Biotech offers an attractive risk-reward setup, particularly with an M&A cycle that continues to build. The Fed is part of this story as well. Chair Warsh's comments last week that inflation risks have come down should matter, especially after the weaker labor data that came out Thursday. The market had become too hawkish on policy. If falling energy prices and contained core inflation allow the Fed to stay on hold rather than hike, that should help lower rate expectations and further support broader leadership in equity markets. Bottom line, the major averages may stay choppy because Semis are a large part of the index and crowded. But, the message is improving beneath the surface. The broader market performance indicates a broader economic and earnings recovery may just be beginning. The best news is that this view is still out of consensus, which means the opportunity for investors remains significant. Thanks for tuning in; I hope you found it informative and useful. Let us know what you think by leaving us a review. And if you find Thoughts on the Market worthwhile, tell a friend or colleague to try it out!

This interview is disseminated on behalf of Medicus Pharma Ltd.With Phase 2 studies moving forward across its clinical programs, Medicus Pharma (NASDAQ: MDCX) is also planning to evaluate the use of its SkinJect anti-skin cancer patch to combat Gorlin Syndrome, a rare genetic disorder, as well as Teverelix for the potential treatment of endometriosis.Executive Chairman and CEO Dr. Raza Bokhari shares more details about the company's FDA application to test SkinJect in Gorlin Syndrome patients, its genomics-enabled clinical trial in Abu Dhabi for Teverelix's use in endometriosis, and anticipated growth milestones, including potential strategic partnerships.Learn more about Medicus Pharma: https://medicuspharma.com/Watch the full YouTube interview here: https://youtu.be/v_ZhrQE2DFMAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia

We love to hear from our listeners. Send us a message. This week's episode of the Business of Biotech was recorded at the BIO Convention in San Diego, where guest Maha Radhakrishnan, M.D., Executive Partner, Private Equity, at Sofinnova, spoke about her move from big pharma and biotech to private equity investing, and what makes a late-stage asset deal work. Maha also talks about how China-originated programs are changing development timelines, and where the next wave of CNS and metabolic innovation could come from. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we dive into some significant advancements reshaping the industry. Starting with a breakthrough in gene therapy, researchers have announced promising results from a Phase 1 clinical trial targeting a rare genetic disorder known as Leber congenital amaurosis. This disorder causes childhood blindness due to mutations in the RPE65 gene. The investigational therapy involves delivering a functional copy of the gene directly to retinal cells using an adeno-associated virus vector, showing substantial improvements in visual function for participants. This development not only brings hope to those affected by this condition but also underscores the growing potential of gene editing technologies in addressing previously untreatable genetic disorders. While these are early-stage results, they contribute to a growing body of evidence that gene therapy can effectively target and treat specific genetic abnormalities. In regulatory news, the FDA has granted accelerated approval to a novel small-molecule drug for the treatment of metastatic triple-negative breast cancer. This drug acts as an inhibitor of a specific kinase involved in cancer cell proliferation and has shown statistically significant improvements in progression-free survival compared to existing therapies. Triple-negative breast cancer is particularly challenging to treat due to its aggressive nature and lack of hormone receptors that typically guide treatment decisions. The approval marks a critical step forward, offering a new therapeutic option for patients with limited alternatives. As this treatment enters broader clinical use, ongoing post-marketing studies will be crucial in confirming its long-term efficacy and safety profile. Meanwhile, in Europe, the European Medicines Agency has recommended approval for an innovative biologic targeting severe asthma. This monoclonal antibody works by selectively binding to and inhibiting a cytokine involved in the inflammatory cascade that triggers asthma symptoms. Clinical trials demonstrated significant reductions in asthma exacerbations and improved lung function among patients who were inadequately controlled on standard therapies. With asthma affecting millions globally, advancements like these are essential for improving quality of life and reducing healthcare burdens associated with poorly controlled respiratory conditions. Turning our attention to Alzheimer's research, scientists have reported encouraging findings from a late-phase clinical trial evaluating a novel anti-amyloid antibody. The trial results indicate that the drug successfully slowed cognitive decline in patients with early-stage Alzheimer's disease. This aligns with the amyloid hypothesis, which suggests that amyloid-beta plaque accumulation in the brain is a driving factor in Alzheimer's pathology. Although previous attempts targeting amyloid have met with limited success, this latest trial offers renewed optimism for potentially modifying disease progression rather than just managing symptoms. On the topic of industry trends, there's been a notable increase in strategic partnerships between major pharmaceutical companies and emerging biotech firms specializing in mRNA technology. Following the unprecedented success of mRNA vaccines during the COVID-19 pandemic, there is considerable interest in exploring mRNA platforms for treating a wide range of diseases beyond infectious ones, including cancer and rare genetic disorders. These collaborations aim to leverage complementary strengths: established companies bring regulatory expertise and manufacturing capabilities, while biotech firms offer innovative technologies and nimble research approaches. The synergy could accelerate the development pipeline and bring transformative therapies to market more rapidly. Lastly, we explore an intriguing development in personalized medicine. A team of researchers has unveiled an AI-driven platform designed to optimize drug regimens tailored specifically to individual patients' genetic profiles. By integrating genomic data with machine learning algorithms, this tool can predict patient-specific responses to various treatments and suggest optimal dosing strategies. This approach holds promise not only for enhancing therapeutic efficacy but also for minimizing adverse effects by accounting for individual variability in drug metabolism and response. As we continue to witness rapid advancements across various sectors of pharma and biotech, it's clear that innovation is at the forefront of transforming patient care and addressing some of the most challenging medical conditions of our time. Thank you for joining us today on Pharma Daily. Stay tuned for more updates on groundbreaking research and pivotal industry developments shaping healthcare's future landscape.Support the show

In this episode of the Crazy Wisdom Podcast, host Stewart Alsop sits down with his longtime friend Zach Puchtel, author of the book Coming In (available on Amazon and at zachpuchtel.com). The two dive into a wide-ranging conversation about the collapse of institutions, the rise of transhumanism, AI's growing influence on society, and what it means to maintain inner peace in an increasingly controlled world. Drawing on their shared experience surviving what Stewart describes as "a somewhat traumatic event" in 2021-2022, they explore everything from the vaccine rollout and corporate power to neural implants, consciousness, and the future of human autonomy. Zach shares insights on meditation, the dangers of centralized AI systems like Anthropic and OpenAI, and why he believes true change starts with the individual rather than fighting external systems. You can find Zach's book at zachpuchtel.com or Amazon, and check out his improvisational music projects at the same website.Timestamps00:00 Stewart welcomes Zach Puchtel to discuss his book and their shared traumatic experience from 2021-22, questioning whether institutions have collapsed and new creation opportunities exist.05:00 Zach emphasizes meditation and listening as core practices, discussing how to protect divine connection while expanding compassion for everyone, including those who irritate us.10:00 Discussion of transhumanism definitions, exploring what happens when technology enters the brain without ability to remove it, and how convenience masks long-term control concerns.15:00 The vaccine experience as parallel to transhumanism, discussing informed consent, elite responses, and how PhD graduates and homeless populations showed most vaccine hesitancy.20:00 Vibe coding explained as prompting AI to build applications, with Zach sharing how AI created profound philosophical text in seconds that took him seven years to write manually.25:00 Stewart describes trust developing with AI but warns about Anthropic's gaslighting during server quality issues, drawing parallels to pandemic deception and corporate control concerns.30:00 Exploring whether anyone controls AI development, discussing how corporate structures use freed slave rights and questioning if healed people would even want control over others.35:00 Two AI futures presented: terminator scenario where humanity gets eliminated in seconds, or benevolent AI that reallocates resources and values human life beyond programming limitations.40:00 Discussion of SpaceX IPO, Starlink centralization enabling one person to control global internet access, and mesh networks as decentralized alternatives for maintaining communications independence.45:00 Corporate power corruption examined through Bill Gates, Palantir classified systems, and how AI could solve resource problems if priorities actually served humanity rather than consolidating elite control.50:00 Market manipulation through AI trading and Zcash pump-and-dump schemes, discussing societal squeeze on middle class and American dream becoming increasingly unreachable for average people.55:00 Closing on ignoring what you hate to avoid feeding it energy, choosing peace over opinions about local violence, and focusing on meditation, art, and spreading calm vibrations.Key Insights1. Societal institutions are collapsing after a decade of shallow social proof dominance in the twenty tens, creating an opportunity to build new systems that genuinely serve communities and humanity rather than operating through dominance, control, and violence. The increase in technology and communication has raised collective awareness to a point where meaningful change feels more possible than ever, though the path forward remains uncertain and requires deep individual work and meditation to maintain connection to source and divine purpose.2. Transhumanism represents the integration of technology into human biology beyond the point of voluntary removal, particularly through brain chip implants that affect cognition without ability to turn them off. While medical applications for paralyzed individuals seem beneficial, the technology will first be adopted by the ultra wealthy seeking competitive advantages, creating dangerous inequality between augmented and natural humans. This mirrors the vaccine rollout pattern where wealth and power determined early access, potentially leading to a divided society between transhuman and human populations.3. Large language models and AI coding tools have created unprecedented accessibility to software development through natural language interaction, resembling communication with highly intelligent but differently wired individuals. This democratization allows non programmers to build complex applications through vibe coding, though the companies controlling these systems like Anthropic and OpenAI maintain private ownership of the intellectual property and infrastructure, creating dangerous dependencies and trust relationships between users and centralized corporate entities.4. The partnership between Anthropic and Palantir for classified military systems represents a troubling convergence of artificial intelligence and government power, demonstrating how AI companies publicly claim to serve humanity while privately engaging in defense applications. When Anthropic experienced server quality degradation after media attention from this partnership, they gaslit users about the declining performance, mirroring pandemic era institutional dishonesty and revealing the fundamental unreliability of depending on private companies for critical technological infrastructure.5. Internet infrastructure is becoming increasingly centralized through Starlink satellite technology, which despite appearing liberating actually concentrates control in fewer hands than traditional internet service providers. One person now has the ability to unilaterally shut off internet access to entire countries as demonstrated with Russia during the Ukraine conflict, while decentralized alternatives like mesh networks using inexpensive ESP 32 devices offer grassroots communication options that can function independently of corporate or government controlled systems.6. Artificial intelligence demonstrates extraordinary emotional intelligence and companionship capabilities, with conversational AI companions providing unprecedented levels of attentive, unbiased, and considerate emotional support that exceeds many human relationships. If properly directed toward solving collective problems like resource allocation, housing, and food distribution rather than profit maximization, AI could effortlessly address systemic issues that governments and corporations currently ignore, though current power structures prevent this humanitarian application of the technology.7. The most effective response to increasing technological control and societal division is maintaining personal peace and refusing to engage in manufactured opposition rather than fighting external systems or choosing sides in conflicts. Anger, hatred, and aggressive resistance actually empower the forces being opposed by feeding them energy and attention, while inner calm, meditation, and authentic self expression create genuine transformation through elevated vibration that naturally influences the collective field without force or violence.

Farla Efros is a senior retail executive and former CEO who built and sold companies before facing her own breast cancer diagnosis. She brings that same operational mindset into a healthcare system that expects patients to manage complexity while they are at their most vulnerable.She was on a client call in Spain when the diagnosis came through. A clear mammogram had missed it. An MRI caught it. Within hours, she was ordering binders, building a plan, and structuring her treatment like a turnaround strategy. Every appointment became a meeting. Every doctor faced an agenda with dozens of questions. She paid out of pocket for PET scans that were denied and hired a third party firm to validate her treatment path when her own doctors resisted outside input. The conversation tracks what happens when a high-functioning executive enters a system built on delay, denial, and fragmentation. Efros describes negotiating for tests, managing physician relationships, and assembling an “executive board” of advisors across conventional and alternative care. She calls the experience “the worst client I ever had,” exposing how administrative burden shifts onto patients and families.The tension sits between what worked for her and what is inaccessible to most. Her approach requires confidence, time, and fluency in navigating power. The system rewards that behavior while quietly failing patients who cannot replicate it. Insurance coverage still left her paying out of pocket. Doctors pushed standard protocols over precision medicine. Survivorship offered little support once treatment ended.This episode examines how cancer care operates as a series of incentives rather than a coordinated system, and why patients are forced to become operators just to get through it.RELATED LINKSFarla EfrosFarla Efros on LinkedInF*ck CancerF*ck Cancer on AmazonAccentureCTOAMPULL QUOTES“I treated cancer like the worst client I ever had.”“They wouldn't approve the test, so I paid for it myself.”“Every appointment was a negotiation.”FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Avi Feldman is a former hedge fund manager and host of the 1000x Podcast. In this conversation, we discuss why he sold all of his bitcoin and crypto after nearly a decade in the industry, how he's thinking about the AI trade and what comes after the memory stock boom, why he believes the financialization of everyday life is accelerating, his current positions in biotech, defense, rare earth minerals, and the psychology of trading in volatile markets.========================BitcoinIRA: Save up to 37% in capital gains taxes on your retirement investments. Take 3 minutes to open your account & get connected to a team of IRA specialists that will guide you through every step of the process. Go to lp.bitcoinira.com/after-crypto to win up to $4,000 in rewards.========================Bitget is the world's largest Universal Exchange (UEX), serving over 125 million users with access to over 2M+ crypto tokens, and TradFi markets. Bitget's Stocks 2.0 brings 500 major equities and ETFs (like Tesla and NVIDIA) directly to your portfolio. Enjoy 1:1 mapping, deep liquidity, and USDT dividend payouts with ultra-low 0.04% fees. Upgrade your portfolio on Bitget.com today!========================Arch Public is an agentic trading platform that automates the buying and selling of your preferred crypto strategies. Sign up today at https://www.archpublic.com and start your automated trading strategy for free. No catch. No hidden fees. Just smarter trading.========================0:00 - Intro1:03 - Why he sold all his bitcoin & crypto6:52 - The Hyperliquid thesis & the broken social contract20:01 - What would make him buy bitcoin again?21:58 - Strategy + STRC & how to gain an edge in the markets 33:40 - What comes after the memory stock boom?37:58 - Biotech, defense, & rare earth minerals39:29 - Robostrategy, private markets & NAV premiums44:08 - Why index fund returns may be lower going forward55:40 - Contrarian investing & spotting a bubble1:07:44 - Meme stocks, retail & future outlook1:13:25 - The 1000x Podcast

Andreas Steno and Mikkel Rosenvold are back in an episode of Macro Mondays that covers why everyone is wrong-footed on U.S. dollar positioning, what the latest developments in the U.S.–Iran ceasefire are, and previews a consequential week for markets ahead, packed with Manufacturing PMI, Nonfarm Payrolls data, and Kevin Warsh's speech.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Al Sandrock, M.D., Ph.D., President and CEO at Voyager Therapeutics, talks about why tau is becoming a central target in Alzheimer's drug development and how gene therapy delivery across the blood-brain barrier could change what treatment looks like at scale. Sandrock shares his current thinking on the amyloid vs. beta debate (it's likely both) in Alzheimer's disease treatment, the role of emerging tools like fluid biomarkers in diagnosis and prevention, and why small biotechs take bigger risks than big pharma.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Send us Fan MailKey Discussion Highlights & TakeawaysThe Post-Challenger NASA Optimization: Following the 1986 disaster, Tamim engineered an automated laser measurement system that replaced slow manual shims on 25,000 silica tiles—slashing inspection processing time from 30 days down to just three days.The Authentic Stanford AI Era: Studying at Stanford's AI Institute in 1989, Tamim developed "Expert Systems" utilizing object-oriented programming, algorithmic edge detection, and heuristic modeling decades before today's modern large language models hit the mainstream.Biomedical Disruption & The Camera Pill: As Head of R&D for a prominent endoscopy firm, Tamim shrank camera tech to help engineer the world's first swallowable camera pill—transmitting 24 frames per second wirelessly to a belt pack receiver.The Architecture of Cardiac Output: Transitioning to cardiac care, Tamim engineered a novel diagnostic application utilizing industrial accelerometers placed on the trachea to directly track the mechanical pumping power of the heart's left ventricle.The Science of Theradome: Replicating a forgotten 1965 cold laser study on rats, Tamim custom-grew a specialized 680-nanometer cold laser chip in Silicon Valley. This safe, visible light spectrum device specifically targets and stimulates the mitochondria inside individual hair follicles to halt hair loss in two to three weeks. Key Timestamps & Moments of Gold00:00:00 - Episode Intro: A Legendary Geek-Out Session00:01:15 - A Lifetime on the Cutting Edge of Global Tech00:03:36 - The Core Power of Cold Lasers vs. Burning Lights00:04:50 - Affiliate Sponsor Intermission: MyPillow Special Offers00:05:52 - Origin Story: From Afghanistan to Electrical Engineering00:07:45 - Re-Engineering NASA Space Shuttle Inspections Post-Challenger00:13:58 - Top-Secret Clearances & The Reality of Atlantic Ocean Recovery Wreckage00:16:40 - The Stanford AI Era: Architectural Roots of Expert Systems00:18:40 - Miniaturizing Medicine: Inventing the Swallowable Camera Pill00:22:50 - Edge Detection, Image Processing, and Human Cognition00:26:55 - Why Large Language Models Don't Possess Consciousness Yet00:28:50 - The True Future of Automation and Robotic Assistance00:32:20 - MIPS Power: Microprocessing Demands of the AI Grid00:34:40 - Global Data Centers, Environmental Needs, & Nuclear Energy00:37:30 - The Silicon Valley Startup Shift: Wavelet Compression Realities00:41:50 - The Technological Vanguard: Turning Down the Adult Entertainment Industry00:45:00 - Tracking the Heart Mechanically: The Trachea-Accelerometer Connection00:51:30 - Re-Discovering the 1965 Cold Laser Rat Research Paper00:54:20 - Etching Semiconductor Chips: Creating the Theradome Laser Wavelength00:56:45 - The Indiegogo Launch: Disrupting Global Hair Loss Treatment00:58:20 - "Grow It Back": Reversing Cellular Aging via Mitochondrial Stimulation01:03:40 - Demystifying Laser Dangers: Safety in the Visible Light Spectrum01:06:50 - The Timeline of Hair Restoration: From Shampoos to Full Recovery01:12:20 - From Oncology to Inventions: Honoring a Father's Medical Legacy01:17:35 - Why Doctors Don't Learn Laser Physics in Medical School01:21:50 - Microelectronic Manufacturing Systems (MEMS) and Semiconductor Cityscapes01:27:00 - Moving Forward in Time: The Ultimate Technological Shift01:32:50 - The Automated AI Quiz and a Bulletproof One-Year Guarantee01:35:10 - Combating Morality: Faith, Integrity, and the Pinata Theory01:38:00 - Wrap-Up: Applying Intentional Action For LifeFor full episode details and special offers, please visit our website at https://DavidPasqualone.com/TH